|69.53 -1.46 (-2.06%)||11-28 15:15|
|Targets||6-month :||83.8||1-year :||97.88|
|Resists||First :||71.75||Second :||83.8|
|Supports||First :||64.6||Second :||60.18|
|MAs||MA(5) :||69.18||MA(20) :||66.41|
|MA(100) :||70.5||MA(250) :||72.51|
|MACD||MACD :||0.8||Signal :||0.2|
|%K %D||K(14,3) :||83.8||D(3) :||79.9|
|52-week||High :||100.85||Low :||47.45|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ LNTH ] has closed below upper band by 25.1%. Bollinger Bands are 9.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||71.43 - 71.7||71.7 - 71.97|
|Low:||67.29 - 67.62||67.62 - 67.94|
|Close:||70.46 - 70.96||70.96 - 71.47|
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Mon, 27 Nov 2023
Add Up The Pieces: IVOO Could Be Worth $99 - Nasdaq
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Drug Manufacturers—Specialty & Generic
|Shares Out||68 (M)|
|Shares Float||67 (M)|
|Held by Insiders||2.7 (%)|
|Held by Institutions||100.8 (%)|
|Shares Short||4,840 (K)|
|Shares Short P.Month||4,900 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||10.19|
|Profit Margin||8.6 %|
|Operating Margin||35.1 %|
|Return on Assets (ttm)||8.7 %|
|Return on Equity (ttm)||15.5 %|
|Qtrly Rev. Growth||33.7 %|
|Gross Profit (p.s.)||8.49|
|Sales Per Share||17.66|
|Qtrly Earnings Growth||118.5 %|
|Operating Cash Flow||298 (M)|
|Levered Free Cash Flow||-270 (M)|
|Price to Book value||6.83|
|Price to Sales||3.94|
|Price to Cash Flow||15.99|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|